We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .
Comparison of the effects of torasemide and furosemide in nonazotemic cirrhotic patients with ascites: a randomized, double-blind study.
In a r and omized double-blind trial we compared the effects of torasemide , a new loop diuretic , and furosemide in nonazotemic cirrhotic patients with ascites during a 3-day period in association with potassium canrenoate ( 200 mg/day ) administration . Doses of loop diuretics administered in this trial ( 10 and 25 mg/day of torasemide and furosemide , respectively ) had been shown to be equipotent in healthy subjects .  Torasemide induced significantly greater natriuresis than furosemide ( p less than 0.02 ) , with a twofold greater percentage increase in basal values ( day 1 : 130 % vs. 50 % ; day 2 : 104 % vs. 42 % ; and day 3 : 65 % vs. 26 % , respectively ) . Body weight loss was significantly higher during torasemide ( p less than 0.02 ) administration , and the overall decrease at the end of the treatment was twice as high for furosemide ( 2.5 + /- 0.6 kg vs. 1.3 + /- 0.4 kg , respectively ) . Diuresis was also higher during torasemide administration , but the difference was not significant ( p = 0.08 ) . The extent of kaliuresis observed during the two treatments was almost identical despite the striking differences in the natriuretic response . The effects of the two treatments on plasma electrolytes , creatinine clearance , blood urea nitrogen , mean arterial pressure , heart rate and plasma arginine vasopressin concentration were similar . Both drugs caused increases in plasma renin activity at the end of the treatment , whereas plasma aldosterone concentration slightly increased only after torasemide administration . Despite the presence of a trend toward a more pronounced effect on these parameters after torasemide administration , no significant difference between the two treatments was observed . ( ABSTRACT TRUNCATED AT 250 WORDS
We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .